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Summary 
Experimental autoimmune encephalomyelitis (EAE),  an experimental  model for the study of 
multiple sclerosis, is an autoimmune disease of the central nervous system that can be induced 
in a number of species by immunization with myelin basic protein (MBP). MBP-reactive CD4 + 
T cells, predominantly expressing the V38.2 T cell receptor (TCR), migrate from the peripheral 
lymphoid organs and initiate the inflammatory response in the brain. We have previously shown 
that a single intrathymic injection of MBP or its major encephalitogenic peptide (p71-90), but 
not a nonencephalitogenic peptide (p21-40), induces antigen-specific systemic tolerance and inhibits 
the induction of EAE in Lewis rats. In this study, we investigated the mechanisms of induction 
and maintenance of acquired thymic tolerance in this model. First, we investigated which thymic 
cell is responsible for "induction" of systemic tolerance. Thymic dendritic-enriched cells, isolated 
by plastic adherence, when incubated in vitro with p71-90 and injected intravenously into Lewis 
rats,  were capable of preventing the development  of EAE,  but  his  protection was  lost  in 
thymectomized recipients. In addition, intravenous injection of thymic dendritic cells isolated 
from animals that had been previously injected intrathymically with p71-90 but not p21-40 also 
prevented the development  of EAE. Second, to determine the "effector" mechanisms involved 
in acquired thymic tolerance, we compared TCR expression in the brains of animals with actively 
induced EAE with TCR expression in animals that received intrathymic injection of p71-90 or 
p21-40.  Using a semiquantitative  reverse transcription-polyrnerase chain reaction (RT-PCR) 
technique,  we found increased expression of CD4 and Vfl8.2 message in brains of immunized 
animals compared with those of naive animals. In animals intrathymically injected with p71-90 
but not p21-40,  CD4 and VBS.2 transcript  levels were significantly reduced compared with 
immunized controls. Immunohistologic studies of brain tissue and spleens with specific V~8.2 
and control V310 monoclonal antibodies confirmed these observations in vivo. These findings, 
taken together with recent data demonstrating that activated T cells circulate through the thymus, 
suggest that interaction of thymic dendritic cells with specific TCR of activated peripheral  T 
cells can lead to inactivation of these antigen-specific cells and confirm the role of VB8.2-expressing 
T  cells in EAE. 
E 
xperimental autoimmune encephalomyelitis (EAE)  1 is an 
inflammatory disease of the central nervous system that 
can be induced in a number of species by immunization with 
1 Abbreviations  used  in  this  paper: EAE,  experimental  autoimmune 
encephalomyelitis; GP-MBP, guinea pig myelin basic protein; MBP, myelin 
basic protein; RT,  reverse transcription; TxA2, thromboxane A2. 
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myelin basic protein (MBP) ancl adjuvant (1). In Lewis rats, 
the major encephalitogenic epitope of guinea pig MBP (GP- 
MBP) is peptide 71-90 (2, 3). Nonencephalitogentic epitopes 
of MBP, residues 21-40, for example, are immunogenic and 
can generate a cell-mediated immune response without in- 
ducing disease (4, 5). 
The thymus appears to play a major role in the develop- 
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Volume  182  August 1995  357-366 merit of self-tolerance and may also play a role in acquired 
tolerance in experimental autoimmune (6-9) and transplan- 
tation (10-14) models.  We have recently shown that injec- 
tion of MBP or its encephalitogenic peptide p71-90 into the 
thymus induces systemic tolerance and prevents development 
of EAE in the Lewis rat model. Immunohistologically, there 
was marked reduction of mononudear cell infiltrates and ab- 
sent activation and inflammatory cytokines in the brains of 
intrathymicaUy tolerized animals  (15). The cellular interac- 
tions in the thymus between specific T cells and thymic APCs 
that ultimately lead to induction  of systemic tolerance and 
the effector mechanisms of acquired thymic tolerance are not 
well understood. Agus et al. reported that activated but not 
resting T  cells circulate through  the thymus  and may stay 
there for a prolonged period of time (16). Furthermore, den- 
dritic cells are known for their ability to migrate to T cell-de- 
pendent areas of lymphoid organs (17). These observations 
provide potential mechanisms whereby presentation of im- 
munogenic peptides by specific thymic APCs to activated pe- 
ripheral T  cells circulating through the thymus might lead 
to specific T  cell inactivation (18) and specific systemic toler- 
ance.  We now report results of studies directed at defining 
the thymic APCs that induce specific peripheral T  cell un- 
responsiveness  to EAE in vivo. 
Materials  and Methods 
Induction of EAE.  Lewis rats, 6-8 wk old, were obtained from 
Harlan Sprague Dawley Inc.  (Indianapolis,  IN) or were bred in 
our own animal facility.  EAE was induced by immunizing the 
animals in the foot pad with 50 gg MBP in CFA, which was pre- 
pared by mixing IFA (Sigma Chemical Co., St. Louis, MO) with 
4  mg/ml  mycobacterium (GIBCO  BRL,  Gaithersburg,  MD). 
Scoring of clinical disease was performed as previously described 
(15, 19, 20). Briefly, duration of disease was calculated by counting 
the total number of days from clinical onset to recovery for individual 
animals; mean duration of disease was calculated as the average for 
the whole group. Maximal grade was defined as the highest clin- 
ical grade achieved by individual animals; mean maximal grade was 
calculated as the average for each group. Statistical analysis was per- 
formed using a one-tailed Student's t test (n  =  4-5 per group). 
Disease index is a composite score and was calculated as follows: 
mean duration of disease  x  mean highest disease grade  x  inci- 
dence (19). 
Antigens.  Preparation of guinea pig MBP was performed as pre- 
viously described (19). Peptide sequences 71-90 and 21-40 (p71-90 
and  p21-40)  were obtained  from published  data  (21) and  syn- 
thesized at the Biopolymer Center, Center for Neurologic Dis- 
eases, Brigham and Women's Hospital (Boston, MA). 
Intrathymic Injections.  Animals were injected intrathymically with 
synthetic peptides dissolved in sterile PBS as previously described 
(14, 15). Intrathymic injections were performed with the animals 
under ether anesthesia by exposing the thymus through a small 
suprasternal incision. Volumes of up to 50 #1 can be injected into 
each lobe, without evidence of  leakage, using a 27-30 gauge needle. 
Thymic injections were performed 48-72 h before immunization. 
Isolation of  Nylon Wool-adherent  Cells.  Thymus was isolated from 
naive Lewis animals  and mashed through a metal sieve to obtain 
a single-cell  suspension. The cells were washed and resuspended 
at 2-3  x  106/ml and then incubated for 1 h at 37~  over 20-ml 
nylon wool columns containing 10% FCS in KPMI. The columns 
were washed 5-10 times with RPMI to remove nonadherent T 
cells, and then the columns were tapped for several minutes to 
mechanically dissociate  the adherent cells. These cells were then 
collected and washed before use. 
Isolation of Nflon Wool-nonadherent Primed T Cells.  Draining 
lymph nodes were isolated on day 9 after immunization with GP- 
MBP/CFA and prepared into a single-cell suspension.  The prepa- 
ration was enriched for T cells by depletion of nylon wool-adherent 
cells as described above. The cells were washed and placed in flat- 
bottomed 96-well plates (Fisher Scientific Co., Pittsburgh, PA) at 
2  x  10  s per well and used as responder cells. The ratio of APCs 
to responders was 1:2, 1:5, 1:10, and 1:100 in quadruplicates.  APCs 
were preincubated with 50 gg/ml GP-MBP before being added to 
the responders. 
Enrichment of Dendritic Cells.  A dendritic cell-enriched popu- 
lation was prepared from thymus or spleen according to the method 
reported by Banuls  et al. (22) with minor modifications.  Briefly, 
the isolated  thymus was cut into small fragments and digested in 
RPMI 1640 (Sigma Chemical Co.) containing 2 mg/ml collagenase 
type IV (Boehringer Mannheim GmbH, Mannheim, Germany) for 
15 min at 37~  Digested fragments were filtered through a stain- 
less steel screen.  The cells were then washed in RPMI 1640 and 
resuspended in the same medium supplemented with 10%  FCS 
at 5  x  107 cells/ml and cultured in 10-ml plates  (Costar Corp., 
Cambridge,  MA) for 60 min at 37~  in a 5% CO2 incubator. 
The nonadherent cells were removed by gentle washing with warm 
RPMI medium, and the adherent cells, i.e., dendritic cells and mac- 
rophages, were cultured for 12-16  h  in 10%  FCS-RPMI.  Most 
macrophages remained adherent after this culture period, whereas 
dendritic cells became nonadherent (23). After isolation, the den- 
dritic cell-enriched population consisted mostly of large cells, with 
some small mononuclear cell contamination when viewed under 
phase-contrast  microscopy. Staining with the following monoclonal 
antibodies was performed to identify the populations by flow cytom- 
etry: TCK ot//~/(R 73), ED1 (MCA 341), ED2 (MCA 342), ED3 
(MCA 343), OX-33 (MCA 340), OX-22 (MCA 53), OX-3 (MCA- 
45), and OX-18 (MCA 51). All antibodies and isotype controls were 
purchased from Bioproducts for Science Inc. (Indianapolis,  IN). 
Flow cytometry was performed on a FACSort  |  (Becton Dickinson 
& Co., Mountain View,  CA) and showed that the isolated  cells 
consisted of two distinct populations: a large-cell population that 
was  EDI+,  ED2 +,  ED3-,  OX-33-  (B cell),  CD45K-,  class I 
MHC +, and class II MHC + , consistent with the expected profile 
of dendritic cells (22), and a small-cell population that consisted 
mostly of thymocytes (TCK +, EDI-,  ED2-,  ED3-,  OX-33-, 
class I § , and class II-). These thymocytes constituted 10-20% of 
the total population. Notably, B cell contamination (OX-33) was 
negligible (<1%). The dendritic-enriched cells had the typical den- 
dritic structure when viewed on cytospin slides and strongly ex- 
pressed class-II MHC antigen; some of these cells also expressed 
OX-62, which stains rat veiled cell-enriched populations (24). Func- 
tionally, the dendritic-enriched cells were potent APCs and were 
capable of inducing significant  proliferation (SI  =  700) of a pep- 
tide T cell clone at ratios of dendritic/responder as low as 1:30 (data 
not shown). 
In  Vitro Pulsing of APCs.  Nylon  wool-adherent  cells  or 
dendritic-enriched cells were incubated with antigen at a concen- 
tration of 50 gg/ml for 3 h at 37~  and then washed twice to 
remove excess antigen. 
Reverse Transcr~tion PCR.  Total cellular KNA was extracted 
from brain sections using RNAzol B (Cinna/Biotecx, Friendswood, 
TX), and cDNA was prepared as previously described (25).  We 
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tive transcript levels (25, 26) and modified as follows for use with 
CD4 and VBS.2. Oligonudeotide primers were synthesized by the 
Protein/Nucleic Acid Laboratory, Brigham and Women's Hospital. 
For each primer combination, conditions were optimized to generate 
a single specific band, and sequence analysis confirmed amplification 
of the predicted fragment. Logarithmic ranges of PCK amplification 
were established  as a function of cycle number and cDNA dilu- 
tion. Keaction conditions included 1.25/~1 cDNA (diluted 1:3 parts 
in 1  x  PCR buffer), 1/~M (each) 5' and 3' primers, 10 mM Tris- 
HC1, 50 mM KC1, 1.5 mM MgC12, 0.001% (wt/vol) gelatin, 800 
#M dNTPs, and 0.625 U AmpliTaq DNA polymerase (Perkin Elmer 
Corp., Foster City, CA) in a total volume of 25 /zl. [32p]dCTP 
(150,000  cpm) was  included for quantitative PCR studies.  The 
thermal cycling variables were denaturation at 94~  for 15 s, an- 
nealing temperature as listed for 20 s, and extension for 60 s (with 
a final extension of 7 min at the end of all cycles). Primer sequences, 
annealing temperature, and number of cycles were as follows: 
CD4  5' TGC GAG CTG GAG AAC AAF AAA GAG G 
3' TCA CAG GTC AAA GTG TTG CTG TCG G 
(reference  27) 
(57~  24 cycles) 
V/38.2  5' AAA GGT GAC ATT GAG TTG TAA G 
3' AAG GGC CCA CCA GCT CAG CTC CAC 
ATG GTC AGG (reference  28) 
(62~  32 cycles) 
G3PDH  5' TGA AGG TCG GTG TCA ACG GAT TTG 
GC; 
3' CAT GTA GGC CAT GAG GTC CAC CAC 
(reference 29) 
(58"C,  22 cycles) 
[32p]dCTP incorporated into PCR product bands was measured 
from dried agarose gels on a Phosphorlmager (Molecular Dynamics, 
Sunnyvale, CA) as described (25, 26). PCR amplification with the 
G3PDH housekeeping gene was performed to assess variations  in 
total KNA or cDNA loading between samples. The mean obtained 
from at least three analyses was used to normalize other transcript 
level measurements from the same sample. Corrected values were 
derived by dividing the measured 32p value for the transcript of 
interest by the mean G3PDH value for the sample. Relative tran- 
script levels were then determined from cDNA sets that included 
negative control samples (for which reverse transcriptase had been 
omitted during cDNA synthesis  or water had been used instead 
of cDNA) performed in the same evaluation.  PCK analysis was 
performed in duplicate on all cDNA samples in an experimental 
set. The experimental set included cDNAs from the brains of naive 
rats (n =  3), rats immunized with MBP without treatment to in- 
duce EAE (n  =  5), rats immunized with MBP after intrathymic 
injection of p21-40  as  control (n  =  6),  and  after intrathymic 
injection of p71-90 to inhibit EAE (n  =  6). Each bar in Fig.  2 
represents the mean corrected levels obtained by pooling the levels 
obtained from all animals per group that had been analyzed in dupli- 
cate.  Results were subjected to multivariate analysis of variance 
(MANOVA)  without replication. 
Immunohistology.  The extent of correlation of V~ usage in situ 
with mKNA data was sought by immunohistologic analysis of sec- 
tions of rat brain and spleen sections at day 14 (n  =  3 per group) 
using mAbs to V/~8.2 and control V/310 (PharMingen, San Diego, 
CA). Immunoperoxidase labeling was performed using a sensitive 
four-layer peroxidase-antiperoxidase technique,  as previously de- 
scribed  (15, 20). 
359  Khoury et al. 
Results 
Intrathymic Injection of p71-90 of CP-MBr" Protects Animah 
from e.AE Even After 30-,; D L,y of Im,n,ni .ation.  In our 
initial studies, we showed that intrathymic injection ofp71- 
90 but not p21-40 24 h, 48 h, or 1 wk before immunization 
prevented development of clinical EAE. In the current study, 
animals injected intrathymically with p71-90 or p21-40 were 
immunized 30 d after intrathymic injection and were observed 
for disease. As seen in Fig.  1, animals injected with p71-90 
were completely protected from development of EAE com- 
pared with control animals injected intrathymically with p21- 
40. The incidence in the p21-40 injected group was 5/5 with 
a mean duration of 5.4  +  0.6 d and a mean grade of 3.0  _+ 
0, whereas none of the p71-90-injected animals were sick. 
These observations indicated to us  that  the thymic APCs, 
which are presenting p71-90 to primed T  cells had to have 
the  unique  characteristics  of holding  on  to  antigen  for a 
prolonged period of time. 
Thymic Nylon Wool-adherent Cells Pulsed In Vitro with p 71- 
90 Inhibit EAE.  We tested the hypothesis that thymic nylon 
wool-adherent cells recognize and present antigen to primed 
T  cells. Thymic nylon wool-adherent cells from a naive an- 
imal were pulsed in vitro with  GP-MBP  for 3  h  at 37~ 
and then added to responder T cells at various ratios. Splenic 
nylon wool-adherent cells served as control APCs.  Thymic 
nylon wool-adherent cells were able to present  antigen  to 
primed T  cells (SI  =  24 and  ~ CPM  =  31,611  at  a ratio 
of 1:2, SI  =  30 and  ~CPM  =  39,117 at a ratio of 1:5, SI 
=  11  and  aCPM  =  14,681  at  a ratio  of 1:10,  and SI  = 
2.3 and  a CPM  =  1,780 at a ratio of 1:100). We then tested 
the hypothesis that nylon wool-adherent cells pulsed with 
the encephalitogenic peptide p71-90 and injected intravenously 
lead to systemic tolerance in vivo. We isolated nylon wool-ad- 
herent cells from naive thymus and pulsed them in vitro for 
3 h at 37~  with 50/~g/ml p71-90 or p21-40. The cells were 
then washed twice to get rid of excess peptides and injected 
intravenously into naive Lewis animals. The recipients were 
immunized 48-72 h later with MBP/CFA.  Significant pro- 
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Figure 1.  Protection from EAE even after delay of immunization after 
intrathymic injection. Lewis rats were injected intrathymically with 100 
~g of p71-90 or p21-40 of MBP. 30 d later they were immunized and 
scored  for disease. There were five  animals per group. Each point represents 
the mean score for the group. tection from EAE was seen in animals  injected with p71- 
90-pulsed cells but not with p21-40 pulsed cells, compared 
with unmodified controls (Table 1 a). A dose-response effect 
was observed such that injection of >30  x  106 cells was pro- 
tective, while injection of <30  x  106 cells was not (two ex- 
periments  with  107 and  17  x  106; data not  shown). 
Thymic  but not Splenic Dendritic Cell-enriched  Populations 
Pulsed In Vitro with p71-90 Induce Tolerance to EAE.  To define 
which thymic cells are responsible for induction of unrespon- 
siveness, a thymic dendritic cell-enriched population was pre- 
pared from naive animals.  The cells were pulsed in vitro with 
p71-90 as described above, washed, then injected intravenously 
into  naive  animals  48-72  h  before  immunization  with 
MBP/CFA.  Injection  of 3-4  x  106 cells of this dendritic 
cell-enriched population significantly diminished the incidence, 
severity, and duration of EAE (Table I  b). Again, a dose-re- 
sponse effect was observed such that injection of 1.5  x  106 
cells caused a decrease in severity of disease without affecting 
incidence (data not shown). Furthermore,  injection of 4  x 
106 thymic non-plastic-adherent  cells (after 2 h incubation) 
pulsed in vitro with p71-90 was not protective (Table 1 c), 
providing evidence that the plastic-adherent,  dendritic cell-en- 
riched population (that become nonadherent after overnight 
incubation),  and not contaminating  thymocytes or thymic 
B cells, is responsible for induction of tolerance. Depletion 
of Fc receptor-positive cells from the dendritic-enriched cell 
population by incubation over immunoglobulin-coated plates 
did not result in loss of disease protection,  suggesting that 
potentially contaminating macrophages do not contribute to 
this effect (data not  shown). 
To address the question of whether thymic dendritic cells 
were unique in their capability to induce tolerance, we in- 
jected dendritic-enriched  splenic cells pulsed in vitro with 
p71-90 intravenously into naive recipients, which were then 
immunized. Table 2 shows that a splenic dendritic-euriched 
population pulsed in vitro with p71-90 did not protect the 
recipients  from  EAE.  Furthermore,  parallel  experiments 
showed that injection of p71-90 at a dose of 100/~g intrave- 
nously did not protect animals from EAE (Table 2). This pro- 
vides evidence against the carry-over of peptide by nonspecific 
adherence to cells  as a mechanism  for protection. 
Ttrymectomy before  Injection of  Dendritic-enriched Cells Abrogates 
Pwtectionfwm EAE.  Animals were thymectomized and then 
injected intravenously with thymic dendritic-enriched  cells 
pulsed in vitro with p71-90 and immunized 48 h later. Con- 
trol animals were thymectomized and then immunized. Table 
3 shows that thymic dendritic-enriched  cells were not pro- 
tective when injected into thymectomized recipients. As ex- 
pected,  splenic dendritic-enriched  cells pulsed in vitro and 
injected into thymectomized recipients also were not protec- 
tive.  These data suggest that the native thymus is required 
for induction of tolerance by intravenous injection of antigen- 
pulsed dendritic  cells. 
Transfer of Dendritic-enriched Cells  frora Intrat~mically Injected 
Animals Inhibits EAE.  The observations described above, 
although suggestive, do not provide direct evidence that thymic 
dendritic-enriched  cells are responsible for induction of ac- 
quired  thymic  tolerance.  To  study  this  further,  thymic 
dendritic-enriched  cells were isolated from the thymus of Lewis 
rats 2 d after intrathymic injection of p71-90 or p21-40. After 
Table  1.  Disease Characteristics in Animals Receiving Thymic Nylon  Wool-adherent, Dendritic-enriched, or Non-plastic-adherent Cells 
Mean  Mean maximal 
Number of cells  duration  score 
Type of cells  injected  Incidence  +  SEM  _+  SEM  Index 
a. 
Thymic nylon wool 
adherent  71-90 pulsed  35  ￿  106  2/4  1.25  _+ 0.7*  0.3  _+ 0.3*  0.18 
Thymic nylon wool 
adherent  21-40 pulsed  35  x  106  4/4  6.0  _+ 0  2.75  _+ 0.2  16.5 
Control  0  4/4  5.25  _+ 0.7  3.5  -+ 0.5  18.4 
b. 
Thymic dendritic  enriched 
71-90 pulsed  4  x  106  2/5*  1.8  _+  1.1"  0.8  -+ 0.5*  0.6 
Control noninjected  0  5/5  6.4  _+ 0.4  3.0  _+ 0  19.2 
C. 
Nonplastic  adherent 
71-90 pulsed  4  x  l&  5/5  6.2  +  0.4  2.1  _+ 0.4  13.0 
Control noninjected  0  5/5  6.5  _+ 0.6  2.5  _+ 0.5  16.2 
Data presented are representative of two to four experiments. Each group of animals consists of four to five animals. 
* P  <0.05. 
360  Acquired  Thymic Tolerance in Experimental Autoimmune Encephalomyelitis Table  2.  Disease Characteristics in Animals Receiving  Splenic Dendritic-enriched Cells or Injected Intravenously with 100/zg  of Peptide 
Mean  Mean maximal 
Number of cells  duration  score 
Type of cells  injected  Incidence  +  SEM  _+  SEM  Index 
Splenic dendritic-enriched 
71-90 pulsed  4  x  l&  4/4  5.50  _+ 0.6  2.38  +_ 0.9  13.09 
Injected p71-90 
100/~g IV  0  5/5  4.40  _+ 0.8  2.40  _+ 0.4  10.60 
Control noninjected  0  5/5  4.80  +  0.8  2.60  +_ 0.4  12.48 
Each group consisted of five animals. There were  no significant differences in incidence, duration, or severity of disease between the groups. 
repeated washing,  3-4  x  106 cells  were injected  intrave- 
nously into  naive  animals  without  in  vitro  pulsing.  The 
recipients were immunized  with MBP/CFA 48-72 h  later 
and  observed for  disease.  Fig.  2  shows  that  recipients  of 
dendritic-enriched cells from animals  intrathymicaUy injected 
with  p71-90  were protected  against  EAE  compared  with 
recipients of dendritic-enriched cells from animals intrathymi- 
cally injected with p21-40.  The incidence was two out of 
four in the p71-90 group vs four out of four in the p21-40 
group; the mean maximal grade was 0.5  +  0.3 (p71-90 vs 
2.12  _+  0.52  (p21-40), P  =  0.016;  and the mean duration 
was 2.0 __ 1.2 d (p71-90) vs 7.5 __ 0.6 d (p21-40), P  =  0.004. 
Specific Downregulation of TCR  Vf18.2 Infiltrating T  Cells 
in the Brain.  There  is  evidence that  the  encephalitogenic 
CD4 + T  ceils that initiate the immune response in the rat 
EAE preferentially use the TCR V38.2 (30). We studied the 
expression of this TCR in the brains of naive animals,  animals 
immunized  with  MBP/CFA,  and  animals  intrathymically 
tolerized with the immunodominant  peptide p71-90 or the 
control peptide p21-40.  Brain RNA was extracted and the 
samples analyzed by RT-PCR for expression of V/~8.2,  and 
CD4 messages. G3PDH was used as a reference gene,  and 
quantitation of PCR products was expressed as a ratio of the 
relevant gene to that of G3PDH. Fig. 3 shows that on day 
14 (peak of disease),  immunized  animals  had  significantly 
increased expression of CD4 and V38.2 transcripts  (P =  0.001) 
compared with naive animals. Animals injected intrathymi- 
cally with p21-40 had no significant change in expression of 
these molecules compared with immunized controls, whereas 
animals injected with p71-90 showed significantly decreased 
expression of CD4 and of V38.2  transcripts  (P <0.001). 
Immunohistologic studies with specific mAbs against V38.2 
and a specificity control TCR VB10 confirmed that V38.2 + 
T cells were selectively decreased by intrathymic injection of 
p71-90 compared with p21-40. As shown in Fig. 4, brains 
from animals injected with p21-40 showed 10-20 V38.2 + 
T  cells per high power field, whereas samples from rats in- 
jected  with  p71-90  showed <1  V38.2 +  T  cell  per  high 
Table  3.  Disease Characteristics in Animals Receiving  Thymic or Splenic Dendritic-enriched Cells after Thymectomy 
Mean  Mean maximal 
Number of cells  duration  score 
Type of cells  injected  Incidence  +_  SEM  +_  SEM  Index 
Thymic dendritic-enriched 
71-90 pulsed 
injected  after thymectomy  5  x  106  5/5  4.80  _+ 0.4  2.0  -+ 0.5  9.6 
Splenic dendritic-enriched 
71-90 pulsed 
injected after  thyrnectomy  5  x  l&  5/5  5.20  +_ 0.5  1.8  +_ 0.4  9.4 
Control noninjected 
thymectomized  0  5/5  5.40  _+ 0.5  2.4  _+ 0.4  12.9 
Each group consisted of five animals. There were  no significant differences in incidence, duration, or severity of disease between the groups. 
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Figure  2.  Injection of  dendritic-enriched  cells from animals intrathymi- 
cally injected with MBP peptides.  Dend•ic-enriched  cells were isolated 
from animals injected intrathymically  48 h earlier with p71-90 or p21-40. 
The cells were washed and  injected i.v. into naive recipients  at 4  x  106 
per animal (four animals per group). The recipients were immunized 48 h 
later and  observed  for disease. 
power field,  mAb against V310 was used as a positive con- 
trol antibody and showed comparable infiltration by V310 + 
T cells in the brains of animals injected intrathymically with 
p21-40  or p71-90.  Intrathymic injection of p71-90  had no 
effect on TCR V3 expression in corresponding spleen speci- 
mens, in which the numbers of V38.2 + T  cells were con- 
sistently 50% or less that of V310 + T  cells (Fig.  4).  These 
data indicate that intrathymic injection of p71-90 results in 
specific inactivation of V38.2 before they home to the brain. 
Discussion 
In our previous studies, we determined that thymectomy 
after intrathymic injection and up to day 7 after immuniza- 
Figure  3.  V~8.2 and CD4 message in the brain on day 14 postimmu- 
nization. Total cellular mRNA was extracted  from the brains of animals 
in the groups listed on they axis. The numbers  of animals per group were 
naive, 3; immunized, 5; p21-40 intrathymicaUy  then immunized, 6; and 
p71-90 intrathymically  then immunized, 6.  RT-PCR was performed in 
duplicates on RNA samples from each individual  animal, and the results 
were normalized  to the mean transcript  levels of the housekeeping  gene 
G3PDH. The results  shown represent  the mean of normalized message 
for each group with SEM. 
tion would abrogate acquired thymic tolerance (15). This sug- 
gested that  a thymic cell population was actively involved 
in the induction phase of acquired thymic tolerance. Some 
APCs are capable of presenting antigen in a way that favors 
tolerogenesis (31, 32).  Dendritic cells were shown to  take 
up antigen from the anterior chamber of the eye and trans- 
port it systemically to be presented in the periphery, causing 
immune deviation (33). They are known to express high levels 
of class II MHC (22,  34)  and to capture antigen in an im- 
munogenic form in situ (35).  They are extremely efficient 
APCs in vitro (36,  37)  and in vivo (38).  Our data indicate 
that a population enriched with thymic dendritic cells in- 
cubated in vitro with the encephalitogenic MBP peptide p71- 
90 and injected systemically into naive animals mimics the 
effects  of intrathymic injection of p71-90  (15). 
The dendritic cell-enriched population may be contami- 
nated with other professional APCs (B ceUs or macrophages), 
which potentially could be mediating the tolerogenic effects. 
We show that intrathymic injection of peptide continues to 
be effective at preventing disease even after a 30-d delay in 
immunization. Because the antigen is injected in soluble form, 
it is not expected to be retained as free antigen for a prolonged 
period in the thymus; it is more likely to be retained on the 
surface of APCs. Dendritic cells retain antigen more efficiently 
than macrophages (38,  39), which have a rapid turnover of 
antigen-presenting activity (40),  suggesting that 30 d after 
intrathymic injection, the peptide is more likely to be on the 
surface of thymic dendritic cells than on the surface of mac- 
rophages.  Thymic B cells were shown to mediate neonatal 
tolerance by causing clonal deletion (23),  but our prepara- 
tion contained <1% B cells, as assessed by flow cytometry. 
Dendritic cells adhere to plastic initially but become nonad- 
herent after overnight culture (34),  so washing non-plastic- 
adherent cells after 2 h of incubation removes contaminating 
thymocytes and B cells. This nonadherent cell population was 
incapable of inducing tolerance after in vitro incubation with 
p71-90.  Furthermore, the small size of the dendritic cell-en- 
riched population required in our model strongly argues in 
favor of the dendritic population rather than macrophages 
or B cells because dendritic cells are very efficient APCs (38, 
39).  Carry-over of antigen as a mechanism is unlikely be- 
cause the cells are washed repeatedly before injection, the con- 
trol nonadherent population failed to induce tolerance after 
the same in vitro incubation with antigen, and injection of 
100/~g  of peptide intravenously was not protective. 
In vitro incubation of dendritic cells allowed us to control 
the conditions of the experiment and ensured that the den- 
dritic cells were exposed to the antigen before injection. To 
establish the link between our in vitro system and the in vivo 
intrathymic injection, we isolated dendritic cells from animals 
injected intrathymically with p71-90  or p21-40  and trans- 
ferred them intravenously into naive recipients without in 
vitro pulsing with peptides. Protection of the recipients sug- 
gests that dendritic cells were exposed to antigen in vivo and 
that thymic dendritic cells are mediating acquired thymic toler- 
ance. Dendritic cells have been shown to present antigen and 
prime naive T cells in vivo (38).  Interestingly, in our model, 
362  Acquired  Thymic Tolerance in Experimental  Autoimmune Encephalomyelitis Figure  4.  Immunohistologic analysis,  in serial sections,  of VB usage by T  cells infiltrating brains  of rats immunized with MBP  and injected in- 
trathymically with peptides 21-40 or 71-90.  Shown are sections from the brain and spleen of corresponding rats.  (a) Considerable numbers of V/~8.2 + 
T  cells were present adjacent to cerebellar blood vessels of rats injected with p21-40.  (b) Intrathymic injection of p71-90 was associated with essentially 
complete absence of Vf18.2 + cells within rat brains.  (c) Lesser  numbers of VB10 + T  cells than  VB8.2 + cells were seen in cerebellar areas  of rats  of 
injected intrathymically with P21-40.  (d) Intrathymic injection of p71-90 did not diminish cerebellar infiltration by Vfll0 + T  cells.  (e) VB8.2 + T  cells 
contributed  "~5-10%  of T  cells within periarteriolar T  cell areas  of rat  spleen (rat was injected with p21-40).  (f) Intrathymic injection of p71-90 had 
no effect on the numbers  of Vf18.2 + cells in rat spleen.  (g) Considerably more V~10 + than VflS.2 +  T  cells were seen in the spleens of rats injected 
with p21-40.  (h)  Intrathymic  injection of p71-90  did not  diminish  spleen cell labeling for Vfll0 + T  cells.  Hematoxy!in counterstain;  x400. the outcome of antigen being presented by dendritic cells is 
suppression  of disease  and  suppression  of proliferation of 
primed lymph node cells (15).  This may result from aner- 
gizing/deletion of antigen-specific T  calls (41, 42) or, alter- 
natively, from the generation of an intermediate regulatory 
cell that suppresses  antigen-specific T  cells in vitro and in 
vivo. Trapping of antigen-reactive cells in the spleen or lymph 
nodes, thus preventing them from reaching the target organ, 
is ruled out by the finding that thymectomy  before adminis- 
tration of pulsed dendritic calls abrogates protection. This 
observation suggests that the interaction between dendritic 
ceils  and antigen-specific T  cells may be occurring in the 
thymus, where activated cells can circulate (16).  Although 
the relative number of activated T cells circulating through 
the thymus at any time point is small (43, 44), this process 
may be a dynamic one, and, theoretically, most activated T 
cells may become inactivated or deleted in the thymus over 
a period of time. This is consistent with our previous obser- 
vation that the thymus is required for the induction of toler- 
ance for up to 7 d  after intrathymic injection (15). 
The findings that splenic dendritic cells do not duplicate 
the tolerogenic effect of thymic dendritic ceils and that thymec- 
tomy abrogates" protection from EAE raise the possibility that 
thymic dendritic cells home to the thymus, whereas periph- 
eral dendritic cells are unable to do so. In their work on an- 
terior chamber-associated immune deviation, Wilbanks  et 
al. showed that peripheral APCs were unable to duplicate the 
effect of anterior chamber cells in inducing immune deviation 
unless the peripheral APCs were preincubated with TGF-/$ 
(31,  45). 
How could the interaction between thymic dendritic cells 
and activated T cells result in a tolerogenic signal? The ob- 
servation that maturing thymocytes have very high cell-surface 
expression of receptors for thromboxane A2 (TxA2) (46), a 
potent aggregating and vasoconstrictor agent (47), suggested 
that TxA2 elaborated by thymic stromal cells might act as 
the key signal for cellular events related to T cell development. 
A  TxA2  agonist,  but  not  an inactive metabolite,  induced 
concentration-dependent  DNA  fragmentation  in  CD4 + 
CD8 +  cells  (46),  which  was  inhibited  by  a  specific  an- 
tagonist. Work from Remuzzi et al. in a rat transplantation 
model showed that blocking TxA2 with a specific receptor 
antagonist abrogates acquired thymic tolerance to renal al- 
lografts induced by intrathymic injection of MHC allopep- 
tides (18). Thymic dendritic cells abundantly express the en- 
zymatic machinery to  synthesize TxA2  (48).  We  suggest 
that the interaction between thymic dendritic cells and acti- 
vated T  cells  leads  to  a  series  of events that  involve the 
TxA2/TxA2 receptor, thus triggering intracellular events that 
increase cytoplasmic calcium (49, 50) and resulting in T cell 
anergy or deletion by apoptosis  (46). 
In a murine model of EAE, Cross et al. showed that antigen- 
specific encephalitogenic cells initiate the inflammatory re- 
sponse in the brain, which is perpetuated by nonspecific cells 
recruited from the periphery (51).  In Lewis rats,  the en- 
cephalitogenic T cells preferentially express Vf18.2 (30). We 
show by immunohistology that  the frequency of Vfl8.2- 
expressing cells in the spleens of naive or immunized animals 
is less than that of VB10 expressing cells, whereas in the brains, 
Vf18.2 + cells are equal or more numerous than V~10 + cells 
at the peak of disease, which is consistent with the hypoth- 
esis that VBS.2 + antigen-specific encephalitogenic cells ini- 
tiate the inflammatory response in the brain. We also show 
that animals intrathymically injected with p71-90 expressed 
significantly lower levels of V~8.2 and CD4 message than 
animals injected with p21-40.  This was confirmed at the pro- 
tein level by decreased staining of VB8.2 + cells in the brains 
of intrathymically tolerized animals. Interestingly, there was 
an equivalent number of V~10*  T  cells in  the brains  of 
animals  intrathymically injected with  p21-40  or  p71-90. 
Whether the encephalitogenic cells are anergized or actually 
deleted before homing to the brain is unknown; however, 
we found that in our model administration of IL-2 in vivo 
did not abrogate protection from EAE (data not shown). Since 
one form of anergy is reversible by exposure to IL-2 (52, 53) 
and, in some models, in vivo administration oflL-2 abrogates 
tolerance (41, 54), our observation suggests that IL-2-respon- 
sive anergy is not responsible for the protection that we ob- 
served,  and studies with specific TCR transgenic mice are 
under way to further delineate these mechanisms. 
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